Persistent Therapeutic Burden after Device-Aided Therapy in Parkinson's Disease: Insights from Post-DAT MANAGE-PDAssessment
MOVEMENT DISORDERS CLINICAL PRACTICE, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Basım Tarihi: 2026
- Doi Numarası: 10.1002/mdc3.70861
- Dergi Adı: MOVEMENT DISORDERS CLINICAL PRACTICE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Academic Search Ultimate (EBSCO), Health Research Premium Collection (ProQuest)
- Erciyes Üniversitesi Adresli: Evet
Özet
Background Device-aided therapies (DAT) improve advanced Parkinson's disease (PD), but residual therapeutic burden may persist. Objectives To explore MANAGE-PD as a framework for characterizing residual disease burden after DAT. Methods In this multicenter cross-sectional study, 77 DAT-treated patients underwent independent MANAGE-PD assessment. Clinical characteristics, MANAGE-PD domains, clinician recommendations, and factors associated with Category 3 were analyzed. Results Of 69 evaluable patients, 38 (55.1%) fulfilled Category 3 criteria, but only three (3.9%) were recommended for an additional DAT. Category 3 patients had more advanced disease, greater non-motor burden, poorer quality of life, and higher oral LEDD (907 vs. 450 mg/day). Freezing/gait impairment, painful dystonia, hallucinations, impulse-control disorders, and persistent OFF periods were major contributors. Only Hoehn and Yahr stage and residual oral LEDD remained independently associated with Category 3. Conclusions Persistent therapeutic burden remains common despite DAT. MANAGE-PD may provide a framework for structured post-DAT reassessment.